SCHEMBL22668308

SCHEMBL22668308

CC(C)C(=O)c1cccc(CN)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 3/20 0.60
KDM4E B2RXH2 1/20 0.46
DBH P09172 1/20 0.46
GAA P10253 1/20 0.46
RECQL P46063 1/20 0.46
ENPP2 Q13822 1/20 0.46
CFD P00746 2/20 0.43
NOS1 P29475 4/20 0.42
NOS2 P35228 4/20 0.42
PNMT P11086 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NOS3 P29474 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP3A4 P08684 1/20 0.41
NFKB1 P19838 1/20 0.41
SLC7A5 Q01650 2/20 0.41
HTR2C P28335 1/20 0.41
FOLH1 Q04609 1/20 0.41
ANPEP P15144 1/20 0.41
ENPEP Q07075 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10277237 0.84 BCL2 (0.47) LOXL2KDM4EDBHGAARECQL
SCHEMBL14519856 0.82 GAA (0.46) LOXL2KDM4EDBHGAARECQL
SCHEMBL10019208 0.82 FOLH1 (0.46) KDM4EDBHGAARECQLSLC7A5
SCHEMBL15761203 0.82 GAA (0.46) LOXL2KDM4EDBHGAARECQL
SCHEMBL10819620 0.81 LOXL2 (0.55) LOXL2KDM4EDBHGAARECQL
SCHEMBL20330179 0.81 ITGA4 (0.51) LOXL2KDM4EDBHGAARECQL
SCHEMBL28275646 0.81 LOXL2 (0.54) LOXL2ENPP2CFDNOS1NOS2
SCHEMBL7945435 0.80 GAA (0.59) KDM4EDBHGAARECQLALDH1A1
SCHEMBL2642751 0.79 LOXL2 (0.66) LOXL2ENPP2CFDNOS1NOS2
SCHEMBL24138282 0.79 GAA (0.43) LOXL2KDM4EDBHGAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023099669-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2023-06-08 WO disclosed
US-11046695-B2 Fragment synthesis of substituted cyclic peptides ZEALAND PHARMA A/S (DK) 2021-06-29 US disclosed
US-20200361944-A1 FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES ZEALAND PHARMA A/S (DK) 2020-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046695-B2 Fragment synthesis of substituted cyclic peptides VIP, NPPA, NGLY1 LOXL2 3424/4885KDM4E 4730/4885DBH 1649/4885
US-20200361944-A1 FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES VIP, NPPA, NGLY1 LOXL2 3809/4885KDM4E 4748/4885DBH 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.